- Evorel® Conti is a continuous combined HRT preparation.
- Patches applied to the skin twice weekly
- Evorel® Conti should not be applied on or near the breasts
Indication:
Hormone replacement therapy (HRT) for the relief of menopausal symptoms in post-menopausal women more than 6 months post-menopause.
Efficacy:
Following first use of an Evorel Conti patch by post-menopausal women, serum estradiol levels rise within 23 hours (T max, single application) from, on average, -18 pmol/L (-5 pg/ml) by an average of 150 pmol/L (41 pg/mL) (C max, single application).
In clinical trials relief of menopausal symptoms was achieved during the first few weeks of treatment
Safety:
In women with an intact uterus the risk of endometrial hyperplasia and carcinoma is increased when oestrogens are administered alone for prolonged periods.
Having Estradiol and Norethisterone combined in the Evorel Conti patch means that the patient will not miss a dose of progesterone which prevents this risk and protects the Endometrium.
1. Evorel Conti Summary of Product Characteristics available on medicines.ie
50/170 micrograms per 24 hours transdermal patch
estradiol hemihydrate and norethisterone acetate
